A biological monoclonal antibody targeting the KIT (CD117) receptor; blocks KIT/stem cell factor signaling to suppress and deplete mast cells, aiming to reduce mast cell–driven inflammation in eosinophilic esophagitis.
Monoclonal antibody targeting KIT (CD117) that blocks stem cell factor (SCF)–KIT signaling, suppressing and depleting mast cells and thereby reducing mast cell–driven inflammation (e.g., in eosinophilic esophagitis).
Blocks SCF–KIT survival signaling on KIT+ mast cells, leading to apoptosis and depletion; Fc effector functions may also contribute via ADCC/ADCP against KIT-expressing cells.
Intravenous human polyclonal anti-HBs IgG (brand: Hepatect CP) used as passive immunotherapy before liver resection or transplant; neutralizes HBV virions and HBsAg subviral particles to lower HBsAg, can be internalized by hepatocytes to inhibit HBsAg/virion secretion, and mediates Fc-dependent ADCC against HBV-infected hepatocytes; preclinical data suggest direct anti-tumor effects on HBV-related HCC tumor-initiating cells.
Human polyclonal anti-HBs IgG that passively neutralizes HBV virions and HBsAg subviral particles to lower circulating HBsAg; can be internalized by hepatocytes to inhibit HBsAg and virion secretion; Fc region engages Fc-gamma receptors to mediate ADCC against HBV-infected hepatocytes, with preclinical evidence of direct anti-tumor effects on HBV-related HCC tumor-initiating cells.
Anti-HBs IgG binds HBsAg on infected hepatocytes; Fc engages FcγR+ effector cells to mediate ADCC (and can activate complement/CDC), leading to lysis of HBsAg-expressing cells.
Recombinant humanized anti-EGFR (HER1/ErbB1) IgG monoclonal antibody that binds the extracellular domain of EGFR to block ligand binding and receptor activation, inhibiting downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling; may also mediate ADCC against EGFR-expressing tumor cells.
Humanized anti-EGFR IgG monoclonal antibody that binds the extracellular domain of EGFR (HER1), blocking ligand binding and receptor dimerization/activation to inhibit downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling and tumor cell proliferation; Fc-mediated effector function may also induce ADCC against EGFR-expressing cells.
The anti-EGFR IgG binds EGFR on target cells and engages Fcγ receptors on immune effectors to trigger antibody-dependent cell-mediated cytotoxicity (ADCC; possibly CDC), leading to killing of EGFR-expressing cells.
A bispecific antibody–drug conjugate (ADC) composed of fully human common light-chain antibodies that simultaneously target c-MET (HGF receptor) and EGFR on tumor cells. Dual binding promotes internalization and intracellular release of a cytotoxic payload, killing c-MET/EGFR–expressing cells and concurrently inhibiting MET and EGFR signaling. Administered intravenously as monotherapy every 3 weeks in Phase 1 dose escalation/expansion.
Bispecific antibody–drug conjugate that binds c-MET and EGFR on tumor cells, triggering internalization and lysosomal release of a cytotoxic payload to kill target-expressing cells, while concurrently inhibiting MET and EGFR signaling pathways.
The bispecific ADC binds c-MET on tumor cells, is internalized, and releases a cytotoxic payload in lysosomes that kills the target-expressing cell (with concurrent MET/EGFR signaling inhibition).
A bispecific antibody–drug conjugate (ADC) composed of fully human common light-chain antibodies that simultaneously target c-MET (HGF receptor) and EGFR on tumor cells. Dual binding promotes internalization and intracellular release of a cytotoxic payload, killing c-MET/EGFR–expressing cells and concurrently inhibiting MET and EGFR signaling. Administered intravenously as monotherapy every 3 weeks in Phase 1 dose escalation/expansion.
Bispecific antibody–drug conjugate that binds c-MET and EGFR on tumor cells, triggering internalization and lysosomal release of a cytotoxic payload to kill target-expressing cells, while concurrently inhibiting MET and EGFR signaling pathways.
Bispecific ADC binds EGFR on tumor cells, undergoes target-mediated internalization, and releases a cytotoxic payload in lysosomes, killing EGFR-expressing cells.